The improved financials and clear regulatory path for ALXN1840 suggest reduced near-term dilution risk and a potential catalyst in mid-2026 with the NDA filing. Traders should monitor upcoming EASL and AAN 2026 presentations for further clinical validation.
Price Chart
Executive Summary
Monopar Therapeutics reported its 2025 financial results, showing a reduced net loss and a strengthened balance sheet with $140.4 million in cash, supporting operations into 2027. The company highlighted progress toward a mid-2026 NDA submission for ALXN1840 in Wilson disease and ongoing development of its MNPR-101 radiopharmaceutical programs.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025.
- Net loss for 2025 was $13.7 million ($1.85/share), down from $15.6 million ($4.11/share) in 2024.
- Q4 2025 net loss was $5.2 million, significantly improved from $10.9 million in Q4 2024.
- R&D expenses decreased to $9.9 million in 2025 from $13.0 million in 2024, primarily due to absence of one-time in-licensing costs.
- G&A expenses rose to $6.8 million in 2025 from $3.2 million in 2024, driven by personnel and legal costs.
- Company plans NDA submission for ALXN1840 in mid-2026 for Wilson disease, supported by positive long-term efficacy and safety data.
- Financing activities in 2025 generated approximately $91.9 million from a public offering.
Financial Impact
Reduced annual net loss by $1.9 million and improved quarterly loss by $5.7 million YoY; raised $91.9 million in net proceeds, significantly extending cash runway.
Risk Factors
- Regulatory risk around FDA acceptance and approval of ALXN1840, despite planned NDA submission.
- Increasing G&A expenses may signal rising overhead ahead of commercialization, potentially pressuring margins.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263989 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers